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LETTERS TO THE EDITORFKBP10 and Bruck Syndrome:
Phenotypic Heterogeneity
or Call for Reclassification?To the Editor: We read with interest the recent paper by
Alanay et al., who describe the first human patients with
FKBP10 (MIM 607063) mutations and conclude that
this adds to the growing list of autosomal-recessive non-
syndromic osteogenesis imperfecta (OI) genes (MIM
610968).1 This is in contrast to our experience with an
extremely rare form of OI called Bruck syndrome (MIM
259450 and 609220), in which multiple joint contracture
is a prominent finding.2 Below we show this syndrome
to be caused by a mutation in the same gene.
The index patient in the study family was referred to us
as a neonate after he was found to have severe flexion
deformity of knees, ankles, and to a lesser extent, elbows.
His working diagnosis was arthrogryposis multiplex conge-
nita. After an initial fracture of the femur because of trivial
trauma at the age of 7months, osteogenesis imperfecta was
suspected and subsequently clinically confirmed when he
had multiple other long bone fractures in early childhood.
He was started on parenteral bisphosphanate therapy,
which seems to have helped with his fracture frequency.
He had normal appearance of the sclera and teeth. Surgical
soft tissue release was only partially successful, and the
patient, currently 9 years old, is still unable to walk but
has normal use of the hands and is of normal intelligence
(Figure 1). His radiological findings consist of evidence of
old healed fractures, severe flexion deformities of knees
and ankles, wormian bones, and generalized osteopenia
(Figure 1). Family history is notable for a similarly affected
older brother, currently 13 years old, who has frequent
fractures and multiple joint contractures and who was
also treated successfully with parenteral bisphosphonate.
There are four healthy siblings and parents, who are
healthy and denied consanguinity, but they can trace their
ancestry to the same village in central Saudi Arabia.
Clinical testing for COL1A1 (MIM 120150) and COL1A2
(MIM 120160) in both patients revealed homozygosity
for a previously reported sequence variant (P205A) in
COL1A1, although the pathogenicity is unclear.3 Given
the ambiguity of the result and the fact that Bruck
syndrome has not been linked to COL1A1, we recruited
this family under a protocol approved by the King Faisal
Specialist Hospital and Research Center institutional
review board and obtained written informed consent.
We performed genome-wide SNP genotyping of both
patients as described before assuming that the parents
might be distantly related.4,5 Indeed, only very few blocks
of apparent homozygosity were identified per patient, and306 The American Journal of Human Genetics 87, 306–308, August 1none of them overlapped with either of the two previously
described Bruck syndrome loci, confirming that these
patients have Bruck syndrome 3 (BKS3).6,7 One area of
overlap between the two patients was identified on
17q21.2, spanning 1.5Mb of genomic DNA that contains
91 genes. FKBP10, which encodes FKBP65, an extracellular
matrix binding protein,8 was an attractive candidate in
that interval. Sequencing of the entire coding and the
flanking intronic sequence revealed the presence of a
homozygous 8 bp insertion (c.1023insGGAGAATT) along
with resulting frameshift and premature truncation of
the protein (p.T342GfsX367).
Interestingly, the OI phenotype that Alanay et al.
described in association with the two mutations is much
more severe than the one we describe here.1 It may be
hard to attribute this to the allelic difference because one
of the two mutations described by Alanay et al. causes
in-frame deletion of 11 amino acids from the first pep-
tidyl-prolyl cis-trans isomerase (PPI) domain, whereas our
mutation predicts complete loss of the fourth PPI domain
(Figure 1), so it is quite possible that bisophosphanate
therapy might have played a role in ameliorating the
phenotype in our patients.9 More importantly, the pheno-
type of our patients is classical for Bruck syndrome,whereas
Alanay and colleagues described an apparently isolated
form of osteogenesis imperfecta. The clinical description
by Alanay and colleagues does not focus on the presence
of contractures, and the ‘‘severe deformities’’ are assumed
to be related to fractures. Upon review of Figure 2A of
the Alanay paper, we suggest that the patient has a plantar
and forefoot flexiondeformity of the right foot. In addition,
the webbing formation shown in Figure 2B suggests the
possibility that a pterygium formation preceded the onset
of the bending fracture of that limb.
In view of our findings above, it would be very helpful if
Alanay and colleagues could evaluate in detail the contrac-
ture phenotype of their patients, with particular emphasis
on early infancy prior to the onset of fractures. This would
enable us to determine whether mutations in FKBP10
cause nonsyndromic OI as well as Bruck syndrome or
whether perhaps the patients described in the Alanay
paper should be re-classified as patients with Bruck
syndrome (BKS3).
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Figure 1. A Novel FKBP10 Mutation in Two Siblings with Bruck Syndrome
(A) Clinical photographs of the index patient and (B) his brother showing fixed flexion deformity of the elbows. (C) Note the severe
flexion deformity of the knees in the index patient; the ankles are less severely involved. (D) Thoracolumar spine X-ray showing scoliosis
and osteopenia. Severe protrusion acetabuli and intrmedullary rod fixation of the right femur fracture can also be seen. (E) Schematic
representation of FKBP65 with the location of mutations indicated by arrows. Our mutation is boxed and shown next to the sequence
chromatogram; the inserted 8 bp are indicated by a red line.Faisal Specialist Hospital and Research Center, Riyadh,
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